drugset / Trial / NCT05046353
D-serine AudRem: R33 Phase
Phase 1/2
Suspended
60 enrolled
New York State Psychiatric Institute
Nathan Kline Institute for Psychiatric Research · collabNational Institute of Mental Health (NIMH) · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Schizophrenia is a major public health problem associated with cognitive deficits, such as short and long term memory, executive functioning, attention and speed of processing that are amongst the strongest predictors of impaired functional outcome. In addition, schizophrenia patients show reduced "plasticity", defined as reduced learning. D-serine is a naturally occurring activator of the N-methyl-d-aspartate-type glutamate receptors (NMDAR) in the brain, and this project will assess the D-serine treatment over 16 weeks of a program designed to measure auditory plasticity.
Timeline
- Start
- 2022-12-01
- Primary completion
- 2027-04-01
- Completion
- 2027-09-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D-serine | Unknown | 120 mg/kg | — |